Clinical and histological predictors of long-term kidney graft survival

Nephrology Dialysis Transplantation

Volumn 28, Issue 6, 2013, Pages 1362-1370

  Galichon, Pierre ^a,b,c   Xu Dubois, Yi Chun ^a,c   Finianos, Serge ^a   Hertig, Alexandre ^a,b,c   Rondeau, Eric ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

Author keywords

Clinical marker; Graft survival; Pathology; Prognosis

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

AGE DISTRIBUTION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COLD ISCHEMIA; DELAYED GRAFT FUNCTION; DONOR SELECTION; DRUG EFFICACY; GENOME ANALYSIS; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; HLA MATCHING; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LONG TERM SURVIVAL; MEDICAL DECISION MAKING; NEPHRITIS; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RECURRENT DISEASE; REVIEW; RISK FACTOR; SURVIVAL RATE;

CLINICAL MARKER; GRAFT SURVIVAL; PATHOLOGY; PROGNOSIS;

GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; SURVIVAL RATE;

EID: 84879873633     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs606     Document Type: Review

References (54)

1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450-462
2. Loupy A, Suberbielle-Boissel C, Hill GS et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570
3. Gondos A, Dohler B, Brenner H et al. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation 2012 [Epub ahead of print]
4. El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535
5. Agence de Biomédecine. Annual report, 2010
6. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378: 1428-1437
7. Mengel M, Sis B, Haas M et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570
8. Veroux M, Grosso G, Corona D et al. Age is an important predictor of kidney transplantation outcome. Nephrol Dial Transplant 2012; 27: 1663-1671
9. Tesi RJ, Elkhammas EA, Davies EA et al. Renal transplantation in older people. Lancet 1994; 343: 461-464
10. Roodnat JI, Zietse R, Mulder PG et al. The vanishing importance of age in renal transplantation. Transplantation 1999; 67: 576-580
11. Noppakun K, Cosio FG, Dean PG et al. Living donor age and kidney transplant outcomes. Am J Transplant 2011; 11: 1279-1286
12. Ojo AO, Wolfe RA, Held PJ et al. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968-974
13. Doshi MD, Garg N, Reese PP et al. Recipient risk factors associated with delayed graft function: a paired kidney analysis. Transplantation 2011; 91: 666-671
14. Kayler LK, Srinivas TR, Schold JD. Influence of CIT-induced DGF on kidney transplant outcomes. Am J Transplant 2011; 11: 2657-2664
15. Hellegering J, Visser J, Kloke HJ et al. Poor early graft function impairs long-term outcome in living donor kidney transplantation. World J Urol 2012 [Epub ahead of print]
16. Cai J, Terasaki PI. Induction immunosuppression improves longterm graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511-1515
17. Guerra G, Ciancio G, Gaynor JJ et al. Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol 2011; 22: 1758-1768
18. Snanoudj R, Royal V, Elie C et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11: 2635-2646
19. Stegall MD, Park WD, Dean PG et al. Improving long-term renal allograft survival via a road less traveled by. Am J Transplant 2011; 11: 1382-1387
20. Schnitzler MA, Lentine KL, Axelrod D et al. Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials. Transplantation 2012; 93: 172-181
21. Fernandez-Fresnedo G, Escallada R, Rodrigo E et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 2002; 73: 1345-1348
22. Halimi JM, Buchler M, Al-Najjar A et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant 2007; 7: 618-625
23. Amer H, Cosio FG. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009; 20: 2490-2492
24. Roodnat JI, Mulder PG, Rischen-Vos J et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001; 72: 438-444
25. Panek R, Lawen T, Kiberd BA. Screening for proteinuria in kidney transplant recipients. Nephrol Dial Transplant 2011; 26: 1385-1387
26. Mueller TF, Solez K, Mas V. Assessment of kidney organ quality and prediction of outcome at time of transplantation. Semin Immunopathol 2011; 33: 185-199
27. Seron D, Moreso F, Bover J et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51: 310-316
28. Nicholson ML, Bailey E, Williams S et al. Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation 1999; 68: 236-241
29. Yilmaz S, Tomlanovich S, Mathew T et al. Protocol core needle biopsy and histologic chronic allograft damage index (CADI) as surrogate end point for long-term graft survival in multicenter studies. J Am Soc Nephrol 2003; 14: 773-779
30. Servais A, Meas-Yedid V, Noel LH et al. Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. Am J Transplant 2011; 11: 1456-1463
31. Azevedo F, Alperovich G, Moreso F et al. Glomerular size in early protocol biopsies is associated with graft outcome. Am J Transplant 2005; 5: 2877-2882
32. Mengel M, Chang J, Kayser D et al. The molecular phenotype of 6-week protocol biopsies from human renal allografts: reflections of prior injury but not future course. Am J Transplant 2011; 11: 708-718
33. Park WD, Griffin MD, Cornell LD et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987-1997
34. Meier-Kriesche HU, Schold JD, Srinivas TR et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383
35. Rush D, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 2129-2134
36. Espinoza EH, Gonzalez-Parra C, Macias-Diaz DM et al. Risk factors for Banff borderline acute rejection in protocol biopsies and effect on renal graft function. Transplant Proc 2010; 42: 2376-2378
37. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422
38. Mengel M, Reeve J, Bunnag S et al. Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant 2009; 9: 1859-1867
39. Dickenmann M, Steiger J, Descoeudres B et al. The fate of C4d positive kidney allografts lacking histological signs of acute rejection. Clin Nephrol 2006; 65: 173-179
40. Loupy A, Hill GS, Suberbielle C et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56-65
41. Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 2010; 5: 2363-2372
42. Ponticelli C, Moroni G, Glassock RJ. Recurrence of secondary glomerular disease after renal transplantation. Clin J Am Soc Nephrol 2011; 6: 1214-1221
43. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10: 1517-1523
44. Galichon P, Hertig A. Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside? Fibrogenesis Tissue Repair. 2011; 4: 1-7
45. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010; 21: 1247-1253
46. Hertig A, Bonnard G, Ulinski T et al. Tubular nuclear accumulation of snail and epithelial phenotypic changes in human myeloma cast nephropathy. Hum Pathol 2011; 42: 1142-1148
47. Rastaldi MP, Ferrario F, Giardino L et al. Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 2002; 62: 137-146
48. Hertig A, Verine J, Mougenot B et al. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 2006; 6: 2937-2946
49. Vongwiwatana A, Tasanarong A, Rayner DC et al. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 2005; 5: 1367-1374
50. Kers J, Xu-Dubois YC, Rondeau E et al. Intragraft tubular vimentin and CD44 expression correlate with long-term renal allograft function and interstitial fibrosis and tubular atrophy. Transplantation 2010; 90: 502-509
51. Galichon P, Vittoz N, Xu-Dubois YC et al. Epithelial phenotypic changes detect cyclosporine in vivo nephrotoxicity at a reversible stage. Transplantation 2011; 92: 993-998
52. Hazzan M, Hertig A, Buob D et al. Epithelial-to-mesenchymal transition predicts cyclosporine nephrotoxicity in renal transplant recipients. J Am Soc Nephrol 2011; 22: 1375-1381
53. Hertig A, Anglicheau D, Verine J et al. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008; 19: 1584-1591
54. Li B, Hartono C, Ding R et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947-954